Clinical Trials
74 trialsA Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
SillaJen, Inc.
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Arbele Limited
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Pilatus Biosciences Inc
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Myeloid Therapeutics
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
SHIELD-1
Turning Point Therapeutics, Inc.
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Eureka Therapeutics Inc.
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen Inc.
AFPᶜ³³²T in Advanced HCC
Adaptimmune
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
OUTREACH
Mina Alpha Limited
GEN2
GenVivo, Inc.
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
CNBG-Virogin Biotech (Shanghai) Ltd.
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
DUET-3
Xencor, Inc.
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Blueprint Medicines Corporation
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
Etnova Therapeutics Corp.
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Eisai Inc.
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Bayer
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
DUET-4
Xencor, Inc.
CheckMate 76U
Bristol-Myers Squibb
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
ET-109
Eureka Therapeutics Inc.
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Gradalis, Inc.
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Novartis
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Mereo BioPharma
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
Shanghai AbelZeta Ltd.
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Aeon Therapeutics (Shanghai) Co., Ltd.
MEDI-573-1028
MedImmune LLC